ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "dermatomyositis"

  • Abstract Number: 2623 • ACR Convergence 2024

    Cardiovascular Health Is Suboptimal in Most Patients with Juvenile-Onset Lupus and Dermatomyositis: Baseline Visit Findings from the Lupus Erythematous and Dermatomyositis Stress and Cardiovascular Health Cohort Study

    Kaveh Ardalan1, Angel Davalos2, Hwanhee Hong2, Bryce Reeve2, Christoph Hornik2, M. Athony Moody2, Donald Lloyd-Jones3, Eveline Wu4, Audrey Ward1, Rebecca Sadun5, Jeff Dvergsten6, Ann Reed2, Mark Connelly7 and Laura Schanberg8, 1Duke University School of Medicine, Durham, NC, 2Duke University School of Medicine, Durham, 3Northwestern University Feinberg School of Medicine, Chicago, 4University of North Carolina School of Medicine, Chapel Hill, NC, 5Duke University, Durham, NC, 6Duke University Hospital, Hillsborough, NC, 7Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, 8Duke University Medical Center, DURHAM, NC

    Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) are associated with premature cardiovascular disease (CVD). The American Heart Association (AHA) cardiovascular health (CVH) score is the…
  • Abstract Number: 0825 • ACR Convergence 2023

    A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)

    Rachita Pandya1, Joshua Dan2, Julianne Kleitsch1, Darosa Lim3, Barbara White4 and Victoria P. Werth5, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3University of Pennsylvania, Philadelphia, PA, 4SFJ Pharmaceuticals, Towson, MD, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Current clinical trials in dermatomyositis (DM) are largely focused on muscle improvement, and use the Total Improvement Score (TIS) as the primary efficacy measure.…
  • Abstract Number: 1236 • ACR Convergence 2023

    Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort

    Dawn Gist1, Sarah Molina2, Maria Pereira3, Andrea Ramirez3, Cagri Yildirim-Toruner4 and Marietta De Guzman3, 1Baylor College of Medicine Pediatrics Residency, Houston, TX, 2Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, 3Baylor College of Medicine, Houston, TX, 4Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…
  • Abstract Number: 1972 • ACR Convergence 2023

    Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial

    Christina Charles-Schoeman1, Joachim Schessl2, Rohit Aggarwal3 and and the ProDERM investigators4, 1UCLA Medical Center, Santa Monica, CA, 2Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, 3University of Pittsburgh, Pittsburgh, PA, 4Institutions in Europe and North America, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
  • Abstract Number: 1022 • ACR Convergence 2023

    Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)

    Joseph Fares1, ross Summer1 and Giorgos Loizidis2, 1The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, 2Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA

    Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
  • Abstract Number: 1249 • ACR Convergence 2023

    Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis

    Kaveh Ardalan1, Angel Davalos1, Hwanhee Hong1, Bryce Reeve1, Christoph Hornik1, M. Anthony Moody1, Donald Lloyd-Jones2, Eveline Wu3, Audrey Ward1, Rebecca Sadun4, Jeffrey Dvergsten5, Ann Reed6, Mark Connelly7 and Laura Schanberg1, 1Duke University School of Medicine, Durham, NC, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of North Carolina School of Medicine, Chapel Hill, NC, 4Duke University, Durham, NC, 5Duke University School of Medicine, Hillsborough, NC, 6Duke University School of Medicine, Chapel HIll, NC, 7Children's Mercy Kansas City / University of Missouri-Kansas City School of Medicine, Kansas City, MO

    Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) patients are at high risk for cardiovascular disease (CVD). The American Heart Association cardiovascular health (CVH) construct is…
  • Abstract Number: 2037 • ACR Convergence 2023

    Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology

    COMFORT ANIM-KORANTENG1, YONG EUN2, Okeoghene Akpoigbe2 and AMANDA SAMMUT2, 1Harlem Hospital Center, New York, NY, 2NYCHH- HARLEM, New York, NY

    Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
  • Abstract Number: 1053 • ACR Convergence 2023

    Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease

    Denis Krutko1, Selene Rubino1, Brian Sauer2, Jorge Rojas Jr3, Gary Kunkel1, Jessica A Walsh4, Shardool Patel5, Grant Cannon6 and Tawnie Braaten1, 1University of Utah, Salt Lake City, UT, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3Puget Sound VA and University of Utah, Seattle, WA, 4Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 5Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…
  • Abstract Number: 1255 • ACR Convergence 2023

    Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort

    Sarah Molina1, Dawn Gist2, Marietta De Guzman3, Eyal Muscal4, Jamie Lai2 and Maria Pereira3, 1Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, 2Baylor College of Medicine / Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, Houston, TX, 4Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…
  • Abstract Number: 2461 • ACR Convergence 2023

    Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies

    Iago Pinal-Fernandez1, Jose Cesar Milisenda2, Katherine Pak1, Sandra Muñoz-Braceras3, Maria Casal-Dominguez3, Jose Jiram Torres-Ruiz3, Stefania Dell´Orso4, Faiza Naz4, Gustavo Gutierrez-Cruz4, Yaiza Duque-Jaimez2, Ana Matas-Garcia2, Joan Padrosa5, Francesc J Garcia-Garcia2, Mariona Guitart-Manpel2, Gloria Garrabou2, Ernesto Trallero-Araguas6, Brian Wallit7, Julie Paik8, Jemima Albayda8, Lisa Christopher-Stine8, Tom Lloyd9, Josep Maria Grau2, Albert Selva-O’Callaghan6 and Andrew Mammen10, 1National Institutes of Health, Bethesda, MD, 2Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, 3Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5CIBERER, Barcelona, Spain, Barcelona, Spain, 6Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 7National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, 8Johns Hopkins University, Baltimore, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD, 10NIH, Bethesda, MD

    Background/Purpose: Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome (AS), and inclusion body myositis (IBM). Myositis-specific autoantibodies…
  • Abstract Number: 1155 • ACR Convergence 2023

    Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis

    Haruna Matsuo1, Toshimasa Shimizu2, Tomohiro Koga3, Nozomi Oki4, Mari Kamiya5, Natsuka Umezawa5, Shinsuke Yasuda6, Masataka Uetani7 and Atsushi Kawakami8, 1Nagasaki University, Nagasaki City, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, 5Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 6Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 7Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Nagasaki University, Nagasaki, Japan

    Background/Purpose: Polymyositis/Dermatomyositis (PM/DM) is a chronic inflammatory disease characterized by muscle weakness, and cutaneous manifestations. Although PM/DM exhibits distinct disease phenotypes based on autoantibodies, assessing…
  • Abstract Number: 1587 • ACR Convergence 2023

    Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

    Benjamin Klein, Mack Reynolds, Bin Xu, Mehrnaz Gharaee-Kermani, Amanda Victory, Shannon Loftus, Mary O'Riordan and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI

    Background/Purpose: Autoimmune photosensitivity is observed in type I Interferon (IFN) mediated diseases such as systemic and cutaneous lupus erythematosus (SLE/CLE) and dermatomyositis. Type I IFN…
  • Abstract Number: 2462 • ACR Convergence 2023

    Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications

    Jorge Armando Gonzalez-Chapa1, Jemima Albayda2, Begum Horuluoglu3, Despina Michailidou1, Marina Barguil Macedo1, Lisa Christopher-Stine2, Ingrid Lundberg4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Johns Hopkins University, Baltimore, MD, 3Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden

    Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work…
  • Abstract Number: 1158 • ACR Convergence 2023

    Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection

    Maximiliano Diaz Menindez1, Megan Sullivan2, Benjamin Wang3, Andy Abril3, Vikas Majithia2, Ronald Butendieck3, Colleen T. Ball4 and Florentina Berianu2, 1Mayo Clinic, Phoenix, AZ, 2Mayo Clinic Florida, Jacksonville, FL, 3Mayo Clinic, Jacksonville, FL, 4Mayo Clinic Jacksonville, Jacksonville, FL

    Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
  • Abstract Number: 1588 • ACR Convergence 2023

    Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing

    Xiaoya Pei1, Jia Shi2, Yangzhong Zhou2, Xiao Zhang2, Xiaoman Wang1, Mingwei Tang2, Shuang Zhou2, chanyuan wu2, Jinmin Peng3, Mengtao Li4, xiaofeng Zeng2, Jun Liu5, Houzao Chen1 and Qian Wang2, 1State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China

    Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology